📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
Latest filing: 2026-08-10 18:52
122 analysed today
FollowTelegram
122
Today
149,523
All-time analysed
42,890
Positive
6,652
Negative
91,308
Neutral
8,605
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
6 announcements match the current filters (relevance ≥ 5).
LOTUSEYE Q1 Results: Net Profit up 12.6% YoY to Rs 0.61 Cr; Revenue grows 26% to Rs 17.06 Cr
Lotus Eye Hospital reported a 26.2% YoY increase in revenue from operations to Rs 17.06 Cr for the quarter ended June 30, 2026. Net profit grew by 12.6% YoY to Rs 0.61 Cr, showing a significant recovery from the net loss of Rs 0.32 Cr in the preceding quarter (March 2026). However, profitability was tempered by a sharp 330.7% YoY spike in finance costs and a 28.3% rise in employee benefit expenses. The company maintains a relatively low debt-to-equity ratio of 0.26 based on its Rs 60 Cr net worth.
Confidence: HIGH
What changedThe company has returned to profitability after a loss in the previous quarter and achieved double-digit top-line growth compared to the previous year.
Why it mattersThe results demonstrate operational recovery and volume growth in the eye care segment, though rising interest and personnel costs are putting pressure on net margins.
Revenue (Q1 FY27): Rs 17.06 CrNet Profit (Q1 FY27): Rs 0.61 CrYoY Revenue Growth: 26.2%Finance Cost Increase (YoY): 330.7%EPS (Q1 FY27): Rs 0.30
📅 Short termThe turnaround from a loss-making quarter and strong revenue growth are likely to be viewed positively by the market in the short term.
📈 Long termWhile top-line growth is healthy, the company needs to improve its ROCE (currently 1.2%) and manage rising finance costs to create long-term shareholder value.
⚠ Risk flags
- Sharp 330% YoY increase in finance costs
- Rising employee benefit expenses (up 28% YoY)
- Low historical ROCE of 1.2%
Key Highlights
Revenue from operations increased 26.2% YoY to Rs 17.06 Cr from Rs 13.52 Cr.
Net profit for the quarter stood at Rs 0.61 Cr, up from Rs 0.54 Cr in the same quarter last year.
Finance costs surged to Rs 50.65 lakhs from Rs 11.76 lakhs YoY, a 330.7% increase.
Employee benefit expenses rose 28.3% YoY to Rs 3.65 Cr.
Achieved a turnaround from a net loss of Rs 31.95 lakhs in the preceding quarter (Q4 FY26).
👀 What to Watch
Investors should monitor the sustainability of the 26% revenue growth and observe if the sharp rise in finance costs is due to recent capital expenditure or increased working capital needs.
Lotus Eye Hospital FY26 Revenue up 8.4% to ₹53.7 Cr; Net Profit drops 89% to ₹8 Lakhs
Lotus Eye Hospital and Institute Limited reported a modest revenue growth of 8.4% YoY for FY26, reaching ₹53.71 crore. However, the company's net profit saw a sharp decline from ₹73.93 lakhs in FY25 to just ₹8.04 lakhs in FY26, largely due to increased finance costs and depreciation. The fourth quarter (Q4 FY26) was particularly weak, resulting in a net loss of ₹31.95 lakhs compared to a profit of ₹25.23 lakhs in the same quarter last year. The company significantly increased its debt by approximately ₹11.43 crore to fund capital expenditures, which rose by over ₹10 crore.
Key Highlights
Annual revenue from operations increased to ₹5,371.41 lakhs in FY26 from ₹4,956.25 lakhs in FY25.
Net profit for the full year plummeted by 89% YoY to ₹8.04 lakhs.
Reported a net loss of ₹31.95 lakhs for Q4 FY26 against a profit of ₹25.23 lakhs in Q4 FY25.
Finance costs surged to ₹85.92 lakhs from ₹35.50 lakhs following new borrowings of ₹1,142.97 lakhs.
Property, Plant, and Equipment (PPE) increased to ₹5,918.30 lakhs from ₹4,874.18 lakhs, indicating heavy expansion-led investment.
👀 What to Watch
Investors should exercise caution as the company's expansion has led to a significant spike in debt and interest costs, severely impacting the bottom line. Monitor the next few quarters to see if the increased capacity leads to sufficient revenue growth to cover the higher fixed costs.
Lotus Eye Hospital Approves FY26 Audited Results; Reappoints Internal Auditor
Lotus Eye Hospital and Institute Limited has approved its standalone audited financial results for the quarter and fiscal year ended March 31, 2026. The company reported that the statutory auditors have issued an unmodified opinion, indicating no major concerns in the financial reporting. Additionally, the board has reappointed Mr. P Vishnu Adithan as the Internal Auditor for the financial year 2026-27 to ensure continued internal control oversight. The meeting was held on May 26, 2026, and concluded within 45 minutes.
Key Highlights
Board approved standalone audited financial results for the quarter and year ended March 31, 2026.
Statutory auditors provided an unmodified opinion on the financial statements.
Reappointed Mr. P Vishnu Adithan, Chartered Accountant, as Internal Auditor for FY 2026-27.
The board meeting commenced at 05:15 PM and concluded at 06:00 PM on May 26, 2026.
👀 What to Watch
Investors should examine the detailed financial tables in the full report to evaluate revenue and profit growth. The unmodified audit opinion is a positive indicator of the company's financial transparency.
Lotus Eye Hospital Cancels Voluntary Delisting Proposal from NSE
Lotus Eye Hospital and Institute Limited has decided to withdraw its proposal for voluntary delisting from the National Stock Exchange (NSE). The Board of Directors, in their meeting on March 17, 2026, cited current market conditions and the necessity of maintaining liquidity for investors as key reasons for this decision. Consequently, the company's equity shares will continue to be listed and traded on both the BSE and NSE. This reversal ensures that shareholders retain maximum flexibility and convenience for trading their holdings.
Key Highlights
Board decided not to proceed with the voluntary delisting of equity shares from the NSE
Company will maintain its dual listing status on both BSE Limited and NSE
Decision influenced by current market conditions and the need to ensure investor liquidity
Board meeting concluded at 5:00 PM on March 17, 2026
👀 What to Watch
Investors should view this as a positive development as it preserves liquidity and price discovery across both major exchanges. No action is required as the company will remain publicly traded on both the NSE and BSE.
Lotus Eye Hospital Reports Q3 FY26 Net Loss of ₹26 Lakhs; Appoints New Company Secretary
Lotus Eye Hospital and Institute Limited reported a net loss of ₹26.07 lakhs for the quarter ended December 31, 2025, a decline from a profit of ₹11.58 lakhs in the preceding quarter. While revenue from operations grew 10.6% year-on-year to ₹1,354.96 lakhs, total expenses rose significantly to ₹1,416.07 lakhs, leading to the loss. For the nine-month period ended December 2025, the company's net profit stands at ₹39.99 lakhs, down from ₹48.69 lakhs in the previous year. The board also appointed Mr. Prathish S as the new Company Secretary and Compliance Officer.
Key Highlights
Revenue from operations increased 10.6% YoY to ₹1,354.96 lakhs in Q3 FY26.
Reported a net loss of ₹26.07 lakhs for the quarter compared to a profit of ₹11.58 lakhs in Q2 FY26.
Total expenses rose to ₹1,416.07 lakhs, driven by higher service expenses of ₹276.74 lakhs and employee benefits of ₹313.76 lakhs.
Nine-month net profit declined to ₹39.99 lakhs from ₹48.69 lakhs in the previous year's corresponding period.
Appointment of Mr. Prathish S as Company Secretary & Compliance Officer effective February 13, 2026.
👀 What to Watch
Investors should be cautious as rising operational and employee costs are eroding margins despite steady revenue growth. Monitor the company's cost-management strategies in upcoming quarters to see if they can return to consistent profitability.
Lotus Eye Hospital Q3 FY26 Revenue up 10.6% YoY to ₹13.55 Cr; Swings to Net Loss
Lotus Eye Hospital and Institute Limited reported a 10.6% year-on-year growth in revenue from operations to ₹1,354.96 lakhs for the quarter ended December 31, 2025. Despite the revenue growth, the company reported a net loss of ₹26.07 lakhs for the quarter, compared to a profit of ₹11.58 lakhs in the preceding quarter. Total expenses rose to ₹1,416.07 lakhs, driven by increased service and employee benefit costs. For the nine-month period ended December 2025, net profit declined by 17.9% to ₹39.99 lakhs compared to the previous year.
Key Highlights
Revenue from operations increased 10.6% YoY to ₹1,354.96 lakhs from ₹1,224.69 lakhs.
Reported a net loss of ₹26.07 lakhs in Q3 FY26 versus a profit of ₹11.58 lakhs in Q2 FY26.
Total expenses for the quarter rose to ₹1,416.07 lakhs, exceeding total income of ₹1,378.51 lakhs.
Nine-month net profit decreased to ₹39.99 lakhs from ₹48.69 lakhs in the corresponding period last year.
Appointed Mr. Prathish S as Company Secretary & Compliance Officer effective February 13, 2026.
👀 What to Watch
Investors should monitor the company's rising operational expenses, which have pushed the bottom line into the red despite steady revenue growth. The stock may face short-term pressure due to the quarterly loss and declining nine-month profitability.
